Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06881894 by on-body injector · 1 trial · 1 indication
Cmax of PF-06881894 was defined as maximum serum concentration of PF-06881894. Observed directly from data.
AUClast of PF-06881894 was defined as area under the serum drug concentration-time profile from time 0 to the last quantifiable concentration. Linear/Log trapezoidal method was used.
AUCinf of PF-06881894 was defined as area under the serum concentration-time profile from time 0 extrapolated to infinite time.
| Arm | Type | Description |
|---|---|---|
| PF-06881894 by on-body injector (OBI) | OTHER | PF-06881894 given by on-body injector (OBI) as test arm, 6 mg administered as a single SC injection |
| PF-06881894 by prefilled syringe (PFS) | OTHER | PF-06881894 given by prefilled syringe (PFS) as reference arm, 6 mg administered as a single SC injection |
| Name | Type | Description |
|---|---|---|
| PF-06881894 by on-body injector | COMBINATION_PRODUCT | PF-06881894 given by on-body injector (OBI), 6 mg administered as a single SC injection |
| PF-06881894 by prefilled syringe | COMBINATION_PRODUCT | PF-06881894 given by prefilled syringe (PFS), 6 mg administered as a single SC injection |
Inclusion Criteria: * Healthy male and/or female participants who, at the time of screening, are between the ages of 18 and 65 years, inclusive. * Participants will include healthy individuals, with healthy being defined as no clinically relevant abnormalities identified by a detailed medical histo...
PF-06881894 by on-body injector is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed pharmacokinetic comparability study evaluating the on-body injector relative to a prefilled syringe. The drug is not approved and remains under clinical investigation.
Pfizer, Inc. (NYSE: PFE) is developing PF-06881894 by on-body injector. The company is conducting clinical trials to evaluate the drug's pharmacokinetic comparability when administered via an on-body injector compared to a prefilled syringe in healthy participants.
PF-06881894 by on-body injector is in Phase 1 clinical development. One Phase 1 study has been completed, involving 141 healthy volunteers in the United States. The drug remains investigational and has not been approved by regulatory authorities.
PF-06881894 by on-body injector has one completed clinical trial, NCT05194579, titled "Pharmacokinetic Comparability Study in Healthy Participants - PF-06881894 On-Body Injector Relative to Prefilled Syringe." This Phase 1 study enrolled 141 healthy volunteers in the United States and was a controlled, randomized trial.
PF-06881894 by on-body injector is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A completed study, NCT05194579, assessed pharmacokinetic comparability in healthy volunteers, but the drug has not received regulatory approval.